Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Track-and-Trace Deal’s Failure Leaves California In Control Of Agenda

Executive Summary

Industry groups will continue to search for legislative vehicles to move a national standard that would preempt state laws; near-term, though, manufacturers and distributors must prepare for California pedigree law.

Advertisement

Related Content

FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals
Track-and-Trace Law: Push Begins For 2015 Exchange Standards
FDA Ready To Launch Secure Supply Chain Pilot
Drug Prices Unaffected By Senate Supply Chain, Compounding Bill, CBO Indicates
J&J Building Electronic Drug-Tracking System In Anticipation of California’s E-Pedigree
PDUFA’s ‘Huge’ GMP Change Will Tie Adulteration To Quality System
Supply Chain Safety’s Dual Visions: Pedigree Or Just Serialization
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA Wants Authority To Enforce Track-And-Trace System For Drugs
FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains

Topics

Advertisement
UsernamePublicRestriction

Register

PS054548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel